NOX 0.00% 7.0¢ noxopharm limited

Ann: New Independent Trial Data Supports Potential of Veyonda, page-18

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    WARMTH patients only received a median of three cycles because Lu-PSMA was no longer effective after that point.

    The median of 5 cycles in LuPIN is a big plus for NOX66: the combination of NOX66 and Lu-PSMA worked for a longer time, which is good for patients; and Novartis would be able to charge their fees for additional cycles, which would be good for Novartis.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
7.0¢
Change
0.000(0.00%)
Mkt cap ! $20.45M
Open High Low Value Volume
7.0¢ 7.0¢ 7.0¢ $2.863K 40.90K

Buyers (Bids)

No. Vol. Price($)
1 141114 6.6¢
 

Sellers (Offers)

Price($) Vol. No.
7.0¢ 4493 1
View Market Depth
Last trade - 10.21am 20/06/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.